<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Baldness treatments,1980,2006,5-alpha-reductase,5-alpha reductase,AIDS,Aerobic,Alpha-linolenic acid,Antiandrogen,Antiandrogens,Antifungal drug" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Baldness treatments - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Baldness treatments</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <p>More than half of men are affected by male pattern baldness by age 50, and <b>baldness treatments</b> are estimated to be a US $1 billion per year industry.<sup id="_ref-50percent_0" class="reference"><a href="#_note-50percent" title="">[1]</a></sup> Since the <a href="../../../1/9/8/1980.html" title="1980">1980s</a>, drug therapy has increasingly become a realistic management option for <a href="../../../b/a/l/Baldness.html" title="Baldness">baldness</a> for men and women. Increased understanding of the role of <a href="../../../d/i/h/Dihydrotestosterone.html" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT) in male and female pattern baldness has led to targeted intervention to prevent this hormone from acting on receptors in the scalp. Coupled with chance discoveries and the ever-present lure of a breakthrough involving stem cells and hair multiplication, scientifically proven baldness treatments continue to be an area of research that receives a large amount of funding.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#General_concerns"><span class="tocnumber">1</span> <span class="toctext">General concerns</span></a></li>
<li class="toclevel-1"><a href="#Minoxidil"><span class="tocnumber">2</span> <span class="toctext">Minoxidil</span></a></li>
<li class="toclevel-1"><a href="#Antiandrogens"><span class="tocnumber">3</span> <span class="toctext">Antiandrogens</span></a>
<ul>
<li class="toclevel-2"><a href="#Finasteride"><span class="tocnumber">3.1</span> <span class="toctext">Finasteride</span></a></li>
<li class="toclevel-2"><a href="#Revivogen"><span class="tocnumber">3.2</span> <span class="toctext">Revivogen</span></a></li>
<li class="toclevel-2"><a href="#Ketoconazole"><span class="tocnumber">3.3</span> <span class="toctext">Ketoconazole</span></a></li>
<li class="toclevel-2"><a href="#Saw_palmetto"><span class="tocnumber">3.4</span> <span class="toctext">Saw palmetto</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Copper_peptides"><span class="tocnumber">4</span> <span class="toctext">Copper peptides</span></a></li>
<li class="toclevel-1"><a href="#Spin_Labels"><span class="tocnumber">5</span> <span class="toctext">Spin Labels</span></a></li>
<li class="toclevel-1"><a href="#Diet_and_lifestyle"><span class="tocnumber">6</span> <span class="toctext">Diet and lifestyle</span></a></li>
<li class="toclevel-1"><a href="#Hair_transplant"><span class="tocnumber">7</span> <span class="toctext">Hair transplant</span></a>
<ul>
<li class="toclevel-2"><a href="#Hair_multiplication_.28upcoming_treatment.29"><span class="tocnumber">7.1</span> <span class="toctext">Hair multiplication (upcoming treatment)</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Other_treatments"><span class="tocnumber">8</span> <span class="toctext">Other treatments</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#Footnotes"><span class="tocnumber">10</span> <span class="toctext">Footnotes</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">11</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="General_concerns" id="General_concerns"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: General concerns">edit</a>]</span> <span class="mw-headline">General concerns</span></h2>
<p>It is easier to prevent the apparent 'aging' and falling out of healthy hairs than to regrow hair in <a href="../../../h/a/i/Hair_follicle.html" title="Hair follicle">follicles</a> that are already dormant. There are products that have good success rates with regrowth, including the scientifically proven <a href="../../../f/i/n/Finasteride.html" title="Finasteride">finasteride</a> (marketed in the U.S. as Propecia) and <a href="../../../m/i/n/Minoxidil.html" title="Minoxidil">minoxidil</a> (marketed in the U.S. as <a href="../../../r/o/g/Rogaine_%28drug%29.html" title="Rogaine (drug)">Rogaine</a>, and outside the U.S. as Regaine). Without preventive treatment, in three double-blind, placebo-controlled, randomized studies, 72% of the balding men on placebo had lost hair compared to baseline by 24 months. This is compared to 17% of participants on <a href="../../../p/r/o/Propecia.html" title="Propecia">Propecia</a>.</p>
<p>The prospective treatment of hair multiplication/hair cloning, which extracts self-replenishing follicle stem cells, multiplies them many times over in the lab, and microinjects them into the scalp, has been shown to work in mice, and is currently under development, expected by some scientists to be available to the public in 2009-2015. Subsequent versions of the treatment are expected by some scientists to be able to cause these follicle stem cells to simply signal the surrounding hair follicles to rejuvenate.</p>
<p>The below treatments are some of the most prominent. Generic brands, often with identical chemical structure or the same active ingredients, may be equally effective and are cheaper.</p>
<p>Interestingly, <a href="../../../p/l/a/Placebo.html" title="Placebo">placebo</a> treatments in studies often have reasonable success rates, though not as high as the products being tested, and even similar side-effects as the products. For example, in <a href="../../../f/i/n/Finasteride.html" title="Finasteride">finasteride</a> (Propecia) studies, the percent of patients with any drug-related sexual adverse experience was 3.8% compared with 2.0% in the placebo group.<sup id="_ref-finasteride1_0" class="reference"><a href="#_note-finasteride1" title="">[2]</a></sup></p>
<p>While treating hair loss most successfully is a multi-faceted, ongoing experiment for the individual, there are three principles, sometimes called "The Three P's" that are considered important to help produce success and avoid the somewhat common mistakes that can sabotage treatments. The Three P's are: <b>p</b>roven treatments first, take <b>p</b>ictures, and be <b>p</b>atient. The average hair loss treatment takes a minimum of 6 months to begin working, and sometimes up to 24 months to truly see optimal results. Treating hair loss takes time because of <b>hair cycles</b>. The process of hair loss is the process of "miniaturization," which takes many years. Hairs grow in, cycle into dormancy, and then grow in again several months later. Each time they re-emerge, they do so thinner, shorter, and less pigmented. In time, they become so small that they are no longer noticeable. This can take many years. New hairs only grow in a 2 or 3 year cycle, which is why it can take a year or more to be able to detect the success of a treatment.</p>
<p>This difficulty can be increased because it is speculated that many (scientifically proven) treatments often cause initial periods of shedding, as some resting hair follicles are ejected and a new cycle of growth begins, hopefully with a thicker follicle. Discontinuing all treatment will cause a period of shedding, likely to one's non-treatment baseline, but probably not worse.<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup></p>
<p><a name="Minoxidil" id="Minoxidil"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Minoxidil">edit</a>]</span> <span class="mw-headline">Minoxidil</span></h2>
<dl>
<dd>
<div class="noprint"><i>Main article: <a href="../../../m/i/n/Minoxidil.html" title="Minoxidil">Minoxidil</a></i></div>
</dd>
</dl>
<p><a href="../../../m/i/n/Minoxidil.html" title="Minoxidil">Minoxidil</a> is a <a href="../../../v/a/s/Vasodilator.html" title="Vasodilator">vasodilator</a> and originally was exclusively used as an oral drug (Loniten®) to treat <a href="../../../h/y/p/Hypertension.html" title="Hypertension">high blood pressure</a>. It was discovered, however, to have the side effect of hair growth and reversing baldness, and in the 1980's, Upjohn Corporation received FDA approval to market a topical solution that contained 2% minoxidil to be used to treat baldness and hair loss as <a href="../../../r/o/g/Rogaine_%28drug%29.html" title="Rogaine (drug)">Rogaine</a>.Minoxidil is applied topically to the scalp, and has been shown to promote hair growth in about 25% of men and women, though it may take several months to work. New hair is usually thinner and lighter, like baby hair, and grows mostly on the top of the head, not at the hairline. Its effects may fade with time. Skin irritation is the most commonly reported side effect. Dizziness and increased heart rate are listed side-effects on the UK patient information leaflet.</p>
<p><a name="Antiandrogens" id="Antiandrogens"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Antiandrogens">edit</a>]</span> <span class="mw-headline">Antiandrogens</span></h2>
<dl>
<dd>
<div class="noprint"><i>Main article: <a href="../../../a/n/t/Antiandrogen.html" title="Antiandrogen">Antiandrogen</a></i></div>
</dd>
</dl>
<p><a href="../../../a/n/t/Antiandrogens.html" title="Antiandrogens">Antiandrogens</a> block DHT already produced and present in the blood stream from <i>binding</i> with hair follicles. Their specificity varies greatly from specific antiandrogens such as finasteride which inhibit the conversion of testosterone to DHT by interfering with 5-alpha-reductase to more broad spectrum antiandrogens (<a href="../../../f/l/u/Fluconazole.html" title="Fluconazole">fluconazole</a>, <a href="../../../s/p/i/Spironolactone.html" title="Spironolactone">spironolactone</a>, etc.) which can have serious side effects including <a href="../../../g/y/n/Gynecomastia.html" title="Gynecomastia">gynecomastia</a>. <a href="../../../k/e/t/Ketoconazole.html" title="Ketoconazole">Ketoconazole</a>, (often sold as <a href="../../../n/i/z/Nizoral_Shampoo_df0b.html" title="Nizoral Shampoo">Nizoral Shampoo</a>) and Neutrogena <a href="../../../t/-/g/T-Gel_e81a.html" title="T-Gel">T-Gel</a> have been clinically shown to have antiandrogen properties<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup> and are prescribed by medical professionals or available over the counter depending on the product, concentration and country.</p>
<p><a name="Finasteride" id="Finasteride"></a></p>
<h3><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Finasteride">edit</a>]</span> <span class="mw-headline">Finasteride</span></h3>
<dl>
<dd>
<div class="noprint"><i>Main article: <a href="../../../f/i/n/Finasteride.html" title="Finasteride">Finasteride</a></i></div>
</dd>
</dl>
<p><a href="../../../f/i/n/Finasteride.html" title="Finasteride">Finasteride</a>, marketed as the brand-name drug <i><a href="../../../p/r/o/Propecia.html" title="Propecia">Propecia</a></i>, belongs to a class of drugs called aza-steroids. It is a "<a href="../../../d/i/h/Dihydrotestosterone.html" title="Dihydrotestosterone">DHT</a> <a href="../../../e/n/z/Enzyme_inhibitor.html" title="Enzyme inhibitor">inhibitor</a>" that is FDA approved to inhibit production of DHT through the entire body. It accomplishes this by blocking the production of <a href="../../../5/-/a/5-alpha-reductase.html" title="5-alpha-reductase">5-alpha-reductase</a>, the enzyme responsible for the conversion of free testosterone to DHT. Finasteride is taken orally and has a reported 29-68% success rate (vs. 17-45% in patients receiving a <a href="../../../p/l/a/Placebo.html" title="Placebo">placebo</a>). It is effective only for as long as it is taken; the hair gained or maintained is lost within 6-12 months of ceasing therapy (Rossi, 2004). In clinical studies, finasteride, like minoxodil, was shown to work on both the crown area and the hairline,<sup id="_ref-finasteride1_1" class="reference"><a href="#_note-finasteride1" title="">[2]</a></sup> but is most successful in the crown area.</p>
<p>Finasteride has been shown to be ineffective for treating hair loss in women, and should not even be touched by pregnant or potentially pregnant women, as it has been speculated that it could cause severe birth defects in male fetuses.<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup> However, finasteride's supporters respond that the study was on post-menopausal women whose hairloss was more likely related to the loss of estrogen versus a sensitivity to testosterone. Other studies<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup> have shown that finasteride is effective for many women with follicular sensitivity to androgens. Many doctors do prescribe it, but not without either careful birth control measures or assurance that the woman cannot become pregnant.</p>
<p>Recently, Glaxo Wellcome released another aza-steroid called <a href="../../../d/u/t/Dutasteride.html" title="Dutasteride">dutasteride</a> and marketed as "Avodart", also for BPH. While hair count studies showed that 2.5 mg of dutasteride was about 1.5 times as effective as finasteride for hair regrowth (adding on average 108 versus 72 hair per 1" diameter area), Glaxo stopped FDA hair loss studies after phase II. While the exact reason was never made public, it was leaked that the product was too similar to finasteride, which itself had not lived up to expectations commercially. As such, the 2.5 mg dosage was not released. The FDA trials for BPH continued, and Avodart became the first drug shown to shrink an enlarged prostate in a clinical study. The .5mg version of the drug (shown in the same study to add on average 92 hair to the same area) is increasingly available to hair loss sufferers via the grey-market of online prescription medication, and physicians increasingly willing to prescribe drugs "off-label."</p>
<p>In December 2006, <a href="../../../g/l/a/GlaxoSmithKlein_d9c4.html" title="GlaxoSmithKlein">GlaxoSmithKlein</a> embarked on a new Phase III, six month study in <a href="../../../k/o/r/Korea.html" title="Korea">Korea</a> to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5mg) for the treatment of male pattern baldness in the vertex region of the scalp (types IIIv, IV and V on the Hamilton-Norwood scale).The future impact that this study will have on the FDA's approval or disapproval of Avodart for the treatment of male pattern baldness in the United States is yet to be determined.</p>
<p><a name="Revivogen" id="Revivogen"></a></p>
<h3><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Revivogen">edit</a>]</span> <span class="mw-headline">Revivogen</span></h3>
<p>Revivogen is a non-FDA approved topical DHT inhibitor treatment applied to the scalp, with many ingredients, such as certain <a href="../../../f/a/t/Fatty_acid.html" title="Fatty acid">fatty acids</a>, that are thought, though not proven, to inhibit DHT levels in the scalp and have a positive influence in combating hair loss. Revivogen also contains ingredients that are thought, though not proven, to function as an <a href="../../../a/n/t/Antiandrogens.html" title="Antiandrogens">antiandrogen</a> (see below) that has a positive influence in combating hair loss. Clinical trials are reportedly underway.<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup></p>
<p>Revivogen uses simple mixtures of fatty acids (<a href="../../../g/a/m/Gamma-linolenic_acid.html" title="Gamma-linolenic acid">gamma-linolenic acid</a>, <a href="../../../a/l/p/Alpha-linolenic_acid.html" title="Alpha-linolenic acid">alpha-linolenic acid</a>, and others, which are thought to be inhibitors of <a href="../../../5/-/a/5-alpha_reductase.html" title="5-alpha reductase">5-alpha reductase</a>, both type I and type II <sup id="_ref-liang1_0" class="reference"><a href="#_note-liang1" title="">[3]</a></sup> <sup id="_ref-liang2_0" class="reference"><a href="#_note-liang2" title="">[4]</a></sup> <sup id="_ref-niederprum_0" class="reference"><a href="#_note-niederprum" title="">[5]</a></sup> ), in their free form, that come from the bulk de-<a href="../../../e/s/t/Esterification.html" title="Esterification">esterification</a> of natural oils like <a href="../../../b/o/r/Borage_seed_oil.html" title="Borage seed oil">borage seed oil</a> and <a href="../../../l/i/n/Linseed_oil.html" title="Linseed oil">linseed oil</a>.</p>
<p><a name="Ketoconazole" id="Ketoconazole"></a></p>
<h3><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Ketoconazole">edit</a>]</span> <span class="mw-headline">Ketoconazole</span></h3>
<dl>
<dd>
<div class="noprint"><i>Main article: <a href="../../../k/e/t/Ketoconazole.html" title="Ketoconazole">Ketoconazole</a></i></div>
</dd>
</dl>
<p><a href="../../../k/e/t/Ketoconazole.html" title="Ketoconazole">Ketoconazole</a> is a synthetic <a href="../../../a/n/t/Antifungal_drug.html" title="Antifungal drug">antifungal drug</a> used to <a href="../../../p/r/o/Prophylaxis.html" title="Prophylaxis">prevent</a> and treat skin and fungal infections, especially in <a href="../../../i/m/m/Immune_deficiency.html" title="Immune deficiency">immunocompromised</a> patients such as those with <a href="../../../a/i/d/AIDS_b1c7.html" title="AIDS">AIDS</a>. Because it is both an anti-fungal and also a <a href="../../../5/-/a/5-alpha_reductase.html" title="5-alpha reductase">5-alpha reductase</a> inhibitor, it can help to slow the balding process. <sup id="_ref-HugoPerez_0" class="reference"><a href="#_note-HugoPerez" title="">[6]</a></sup> <sup id="_ref-pierard_0" class="reference"><a href="#_note-pierard" title="">[7]</a></sup> There has been some suggestion that ketoconazole could inhibit testosterone synthesis in utero, which could potentially inhibit genital development of a male fetus. However, this has not been documented in any controlled studies. <sup id="_ref-0" class="reference"><a href="#_note-0" title="">[8]</a></sup></p>
<p><a name="Saw_palmetto" id="Saw_palmetto"></a></p>
<h3><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Saw palmetto">edit</a>]</span> <span class="mw-headline">Saw palmetto</span></h3>
<dl>
<dd>
<div class="noprint"><i>Main article: <a href="../../../s/a/w/Saw_Palmetto_3d0c.html" title="Saw Palmetto">Saw Palmetto</a></i></div>
</dd>
</dl>
<p><a href="../../../s/a/w/Saw_palmetto.html" title="Saw palmetto">Saw palmetto</a> (<i>Serenoa repens</i>) is an <a href="../../../h/e/r/Herbal_medicine.html" title="Herbal medicine">herbal</a> DHT inhibitor which is cheaper than most commercial drugs and is claimed to have fewer side effects than finasteride and dutasteride. Unlike other 5-alpha-reductase inhibitors, saw palmetto extract inhibits the conversion of testosterone to DHT without interfering with the cellular capacity to secrete <a href="../../../p/r/o/Prostate_specific_antigen.html" title="Prostate specific antigen">PSA</a>.<sup id="_ref-habib_0" class="reference"><a href="#_note-habib" title="">[9]</a></sup> Saw palmetto extract has been demonstrated to inhibit both isoforms of alpha-5-reductase unlike finasteride which only inhibits the (predominant) type 2 isoenzyme of alpha-5-reductase.<sup id="_ref-prager_0" class="reference"><a href="#_note-prager" title="">[10]</a></sup> <sup id="_ref-marks_0" class="reference"><a href="#_note-marks" title="">[11]</a></sup> It must be noted that DHT inhibition <a href="../../../i/n/_/In_vitro.html" title="In vitro">in vitro</a> does not necessarily imply inhibition <a href="../../../i/n/_/In_vivo.html" title="In vivo">in vivo</a>. A preliminary study of saw palmetto extract for treating hair loss noted improvement in six of ten subjects over a six month period. Dosages were not reported. <sup id="_ref-prager_1" class="reference"><a href="#_note-prager" title="">[10]</a></sup> The small size of the study and its relatively short duration limit must be noted.</p>
<p><a name="Copper_peptides" id="Copper_peptides"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Copper peptides">edit</a>]</span> <span class="mw-headline">Copper peptides</span></h2>
<p>Copper peptides are applied topically to the scalp, and shorten the resting phase of hairs, resulting in more hair follicles on the scalp being in the growing phase (as opposed to the resting or falling out phase) at one time. Copper peptides generally have <a href="../../../s/u/p/Superoxide.html" title="Superoxide">superoxide</a> <a href="../../../d/i/s/Dismutation.html" title="Dismutation">dismutation</a> activity. See <a href="http://www.drproctor.com/patents/pro876.html" class="external text" title="http://www.drproctor.com/patents/pro876.html" rel="nofollow">US patent 5,470,876, "Topical SOD for treating hair loss"</a>. There is a strong belief in the hair loss treatment community that SOD based treatments may reduce scalp irritation and dandruff often associated with hair loss, and other hair loss treatments.</p>
<p>SOD's likely work by destroying superoxide, the antagonist to <a href="../../../n/i/t/Nitric_oxide.html" title="Nitric oxide">Nitric oxide</a> (NO), the natural form of minoxidil. Superoxide has an "agonist-antagonist" relationship with Nitric oxide or "Endothelium-derived Relaxing Factor". See <a href="http://www.drproctor.com/Archd.htm" class="external text" title="http://www.drproctor.com/Archd.htm" rel="nofollow">"Endothelium-Derived Relaxing Factor and Minoxidil: Active Mechanisms in Hair Growth", <i>Archives in Dermatology</i>, vol 125, August, 1989</a></p>
<p>A product called Tricomin, released by Procyte, based on Copper Peptides was shown in FDA studies to produce results similar to 2% minoxidil. FDA studies were discontinued, according to Procyte, because of the expense. While by today's standards these results are quite sub-par, compounds based on this formula are licensed by Procyte to "cosmo-ceutical" makers, and have been shown in clinical studies to help hair grafts take after the transplant.<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup></p>
<p><a name="Spin_Labels" id="Spin_Labels"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Spin Labels">edit</a>]</span> <span class="mw-headline">Spin Labels</span></h2>
<p>In animal models, the nitroxide spin labels TEMPO and TEMPOL enhance hair regrowth following radiation. National Cancer Institute-sponsored clinical trials <a href="http://clincancerres.aacrjournals.org/cgi/content/full/10/19/6411" class="external text" title="http://clincancerres.aacrjournals.org/cgi/content/full/10/19/6411" rel="nofollow">report</a> TEMPOL is similarly effective in humans. Also see United States Patent 5,714,482 "Topical spin labels and method".</p>
<p><a name="Diet_and_lifestyle" id="Diet_and_lifestyle"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Diet and lifestyle">edit</a>]</span> <span class="mw-headline">Diet and lifestyle</span></h2>
<p>While there are a number of genetic factors which determine a person's susceptibility to androgenic alopecia including androgen receptor polymorphisms, 5-alpha-reductase levels in the scalp, androgen receptor density and distribution in the scalp, and other factors some of which may not have been discovered. Some speculate the increase in baldness in the population of Japan after World War II demonstrates that hair loss can be influenced by diet and lifestyle. Increased fat or caloric intake, decrease in <a href="../../../a/e/r/Aerobic.html" title="Aerobic">aerobic</a> exercise and general "westernization" was accompanied by a dramatic increase in incidence of male pattern baldness.<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup></p>
<p>Skeptics of this analysis believe the westernization that led to increased hair loss in Japan may have occurred in the gene pool, noting the higher propensity of hair loss in American soldiers of European descent stationed in and around Japan after the war.</p>
<p>Daily, vigorous aerobic exercise (as opposed to short workout periods designed to raise androgen levels and build muscle, or more sporadic exercise) and a diet which is adequate yet more moderate in terms of fat and total calorie intake have been shown to reduce baseline insulin levels as well as baseline total and free testosterone<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[12]</a></sup>, which would significantly lower baseline DHT.</p>
<p>Lower insulin levels and reduced stress both result in raised levels of Sex Hormone Binding Globulin (<a href="../../../s/h/b/SHBG_3227.html" title="SHBG">SHBG</a>). SHBG binds to testosterone, and prevents it from circulating free in the blood. Only free testosterone is converted to DHT. It is the level of free androgens and not total androgens which is relevant to the levels of DHT in the scalp and the progression of MPB. In short, aerobic exercise is capable of significantly lowering DHT. <sup id="_ref-barnard1_0" class="reference"><a href="#_note-barnard1" title="">[13]</a></sup> <sup id="_ref-barnard2_0" class="reference"><a href="#_note-barnard2" title="">[14]</a></sup></p>
<p>Androgenic alopecia has been shown to correlate with metabolic syndrome. Medically increasing androgen levels does not worsen this condition, demonstrating that androgens do not cause metabolic syndrome. Instead, high insulin levels (and possibly chronic inflammation <sup id="_ref-joffe_0" class="reference"><a href="#_note-joffe" title="">[15]</a></sup>) seem the likely link in the demonstrated correlation between baldness and metabolic syndrome. This reinforces the notion that behaviors which help to keep insulin levels low and reduce chronic inflammation might also help to preserve hair. <sup id="_ref-cikim_0" class="reference"><a href="#_note-cikim" title="">[16]</a></sup> <sup id="_ref-heald_0" class="reference"><a href="#_note-heald" title="">[17]</a></sup></p>
<p><a name="Hair_transplant" id="Hair_transplant"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Hair transplant">edit</a>]</span> <span class="mw-headline">Hair transplant</span></h2>
<p><a href="../../../s/u/r/Surgery.html" title="Surgery">Surgery</a> is another method of reversing hair loss and baldness, although it may be considered an extreme measure. The surgical methods used include <a href="../../../h/a/i/Hair_transplantation.html" title="Hair transplantation">hair transplantation</a>, in which pieces of skin with hair are implanted onto the scalp's bald areas. Another method is scalp reduction, in which pieces of skin without hair are excised, and the left over skin is pulled together and stitched. Hair transplants generally cause scarring, sometimes major, which may be especially visible if hair loss continues over the rest of the scalp. Hair restoration surgery can also be performed using a micro surgery method such as the Choi implanter method. This procedure is carried out by taking pieces of skin from what's called a donor patch (harvesting follicles from the back of the head), then replanting those harvested follicles into bald areas. The benefit of this kind of procedure is that the transplanted grafts can look very natural.</p>
<p>This procedure can be followed through Seth Garon's blog, Battle Against Bald, where he documents his surgery through each step of the procedure; from consultation, procedure, and through each stage of hair re-growth.</p>
<p><a name="Hair_multiplication_.28upcoming_treatment.29" id="Hair_multiplication_.28upcoming_treatment.29"></a></p>
<h3><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Hair multiplication (upcoming treatment)">edit</a>]</span> <span class="mw-headline">Hair multiplication (upcoming treatment)</span></h3>
<p><a href="../../../s/t/e/Stem_cells.html" title="Stem cells">Stem cells</a> have been discovered in hair follicles and some researchers predict research on these follicle stem cells may lead to successes in treating baldness through <i>hair multiplication</i>, also called <i>hair cloning,</i> within three or four years<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup>. This treatment is expected to initially work through taking stem cells from existing follicles, multiplying them in cultures, and implanting the new follicles into the scalp. Later treatments may be able to simply signal follicle stem cells to transmit chemical signals to nearby follicle cells which have shrunk during the aging process, which respond to these signals by regenerating and once again making healthy hair.</p>
<p>Unfortunately, this new approach to treating baldness appears to be taking longer than expected. The first products are now expected to hit the market in 2009/2010. However, it remains unclear how effective they are going to be. It has been suggested that only future generations of HM will allow patients to grow as much hair as they want.</p>
<p>HM is being developed by two independent companies: ARI (Aderans Research Institute, a Japanese owned company in the USA) and Intercytex, a company in Manchester(<a href="../../../u/k/_/UK_7642.html" title="UK">UK</a>).<sup id="_ref-webmd_0" class="reference"><a href="#_note-webmd" title="">[18]</a></sup> <sup id="_ref-cbs2chicago_0" class="reference"><a href="#_note-cbs2chicago" title="">[19]</a></sup></p>
<p>On <a href="../../../o/c/t/October.html" title="October">October</a> <a href="../../../2/0/0/2006.html" title="2006">2006</a>, <a href="../../../u/k/_/UK_7642.html" title="UK">UK</a> <a href="../../../b/i/o/Biotechnology.html" title="Biotechnology">biotechnology</a> firm <i>Intercytex</i> announced they have successfully tested a method of removing <a href="../../../h/a/i/Hair_follicles.html" title="Hair follicles">hair follicles</a> from the back of the neck, multiplying them and then reimplanting the cells into the scalp. The initial testing resulted in 70% of male patients regrowing hair. This treatment method is expected to be available to the public by 2009 <a href="http://news.bbc.co.uk/2/hi/health/5413382.stm" class="external autonumber" title="http://news.bbc.co.uk/2/hi/health/5413382.stm" rel="nofollow">[1]</a><a href="http://uk.news.yahoo.com/06102006/325/baldness-treating-robot-gets-funding.html" class="external autonumber" title="http://uk.news.yahoo.com/06102006/325/baldness-treating-robot-gets-funding.html" rel="nofollow">[2]</a>. On October 6, 2006, the company was awarded a £1.85 million ($3.63 million) grant by the UK Department of Trade and Industry (DTI) through the Technology Programme to develop an automated manufacturing process for ICX-TRC, Intercytex’s novel hair regeneration therapy. The grant will be used primarily to develop a dedicated robotic system to support the commercial-scale production of dermal papilla (DP) cells, the main cells involved in hair regeneration and the key component of ICX-TRC.</p>
<p>In January 2007, Italian stem-cell researchers say they've come up with a new technique for curing baldness. Pierluigi Santi of a Genoa clinic said stem cells could be used to "multiply" hair roots. He said the clinic would be ready to perform its first hair transplants on priority patients - those who have lost their hair in fires or other accidents - within a few months. After that, he said, "we'll open our doors to paying customers". Santi's approach works by splitting roots and growing new follicles.</p>
<p><a name="Other_treatments" id="Other_treatments"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Other treatments">edit</a>]</span> <span class="mw-headline">Other treatments</span></h2>
<ul>
<li><a href="../../../a/z/e/Azelaic_acid.html" title="Azelaic acid">Azelaic acid</a> - A study found a 90% inhibition of 5-alpha-reductase activity <i>in vitro</i> with an azelaic acid and <a href="../../../z/i/n/Zinc.html" title="Zinc">zinc</a> combination. There was an additive effect between the two compounds.<sup id="_ref-azelaic_0" class="reference"><a href="#_note-azelaic" title="">[20]</a></sup></li>
<li><a href="../../../s/p/i/Spironolactone.html" title="Spironolactone">Spironolactone</a></li>
<li><a href="../../../t/r/e/Tretinoin.html" title="Tretinoin">Tretinoin</a> (aka Retinoic acid and as tradename Retin-A); chemical peel stimulation of scalp)</li>
<li>Regenix</li>
<li>Avacor</li>
<li>LLT or Low-level Laser Therapy - Not FDA approved for hair regrowth, but only as a cosmetic hair enhancer. Treatments are administered at either a clinic or salon (most of which are in Europe), or by the individual user via a home-based portable system (for example, "The Laser Comb"). No official results have been proven or published regarding hair regrowth.</li>
<li><a href="../../../p/u/m/Pumpkin_seed.html" title="Pumpkin seed">Pumpkin seed</a> - Used to aid in the breakdown of DHT by the liver.<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup> An extract is often used, as unprocessed pumpkin seeds are high in fat which can exacerbate hair loss in susceptible patients.</li>
<li><a href="../../../s/t/i/Stinging_nettle.html" title="Stinging nettle">Stinging nettle</a></li>
<li><a href="../../../z/i/n/Zinc.html" title="Zinc">Zinc</a> - While oral zinc supplementation may help prevent the conversion of testosterone to DHT, it also increases total testosterone levels<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup>.</li>
</ul>
<p><br /></p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../b/a/l/Baldness.html" title="Baldness">baldness</a></li>
<li><a href="../../../c/o/m/Comb_over.html" title="Comb over">comb over</a></li>
</ul>
<p><a name="Footnotes" id="Footnotes"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: Footnotes">edit</a>]</span> <span class="mw-headline">Footnotes</span></h2>
<div class="references-small">
<ol class="references">
<li id="_note-50percent"><b><a href="#_ref-50percent_0" title="">^</a></b> Whyche, Stephanie. <a href="http://www.intelihealth.com/IH/ihtIH/WSIHW000/9023/24253/352721.html?d=dmtContent" class="external text" title="http://www.intelihealth.com/IH/ihtIH/WSIHW000/9023/24253/352721.html?d=dmtContent" rel="nofollow">The Bald Truth About Hair Loss In Young Men</a>. Retrieved on <a href="../../../2/0/0/2006.html" title="2006">2006</a>-<a href="../../../j/u/l/July_26.html" title="July 26">07-26</a>.</li>
<li id="_note-finasteride1">^ <a href="#_ref-finasteride1_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-finasteride1_1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal">Layden, J.; Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, et al. (in press). "Finasteride in the treatment of men with frontal male pattern hair loss". <i>J Am Acad Dermatol</i>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Finasteride+in+the+treatment+of+men+with+frontal+male+pattern+hair+loss&amp;rft.title=J+Am+Acad+Dermatol&amp;rft.jtitle=J+Am+Acad+Dermatol&amp;rft.date=in+press&amp;rft.au=Layden%2C+J.">&#160;</span></li>
<li id="_note-liang1"><b><a href="#_ref-liang1_0" title="">^</a></b> <cite style="font-style:normal">Liang, T.; Liao, S. (1997). "Growth Suppression of Hamster Flank Organs by Topical Application of γ-Linolenic and Other Fatty Acid Inhibitors of 5α-Reductase". <i>J Invest Dermatol</i> <b>109</b>: 152-157.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Growth+Suppression+of+Hamster+Flank+Organs+by+Topical+Application+of+%CE%B3-Linolenic+and+Other+Fatty+Acid+Inhibitors+of+5%CE%B1-Reductase&amp;rft.title=J+Invest+Dermatol&amp;rft.jtitle=J+Invest+Dermatol&amp;rft.date=1997&amp;rft.volume=109&amp;rft.au=Liang%2C+T.&amp;rft.pages=152-157">&#160;</span></li>
<li id="_note-liang2"><b><a href="#_ref-liang2_0" title="">^</a></b> <cite style="font-style:normal">Liang, T.; Liao, S. (1992). "Inhibition of 5α-reductase by specific aliphatic unsaturated fatty acids". <i>Biochem J.</i> <b>285</b>: 557-562.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Inhibition+of+5%CE%B1-reductase+by+specific+aliphatic+unsaturated+fatty+acids&amp;rft.title=Biochem+J.&amp;rft.jtitle=Biochem+J.&amp;rft.date=1992&amp;rft.volume=285&amp;rft.au=Liang%2C+T.&amp;rft.pages=557-562">&#160;</span></li>
<li id="_note-niederprum"><b><a href="#_ref-niederprum_0" title="">^</a></b> <cite style="font-style:normal">Niederprum, HJ; Schweikert HU, Thuroff JW, Zanker KS (30 Sept. 1995). "Inhibition of steroid 5 alpha-reductase activity by aliphatic fatty acids. Candidates for chemoprevention of prostate cancer.". <i>Ann N Y Acad Sci.</i> <b>768</b>: 227-230.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Inhibition+of+steroid+5+alpha-reductase+activity+by+aliphatic+fatty+acids.+Candidates+for+chemoprevention+of+prostate+cancer.&amp;rft.title=Ann+N+Y+Acad+Sci.&amp;rft.jtitle=Ann+N+Y+Acad+Sci.&amp;rft.date=30+Sept.+1995&amp;rft.volume=768&amp;rft.au=Niederprum%2C+HJ&amp;rft.pages=227-230">&#160;</span></li>
<li id="_note-HugoPerez"><b><a href="#_ref-HugoPerez_0" title="">^</a></b> <cite style="font-style:normal">Hugo Perez BS (2004). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14729013&amp;query_hl=5&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14729013&amp;query_hl=5&amp;itool=pubmed_docsum" rel="nofollow">Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men.</a>". <i>Med Hypotheses</i> <b>62</b> (1): 112-115.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Ketocazole+as+an+adjunct+to+finasteride+in+the+treatment+of+androgenetic+alopecia+in+men.&amp;rft.title=Med+Hypotheses&amp;rft.jtitle=Med+Hypotheses&amp;rft.date=2004&amp;rft.volume=62&amp;rft.issue=1&amp;rft.au=Hugo+Perez+BS&amp;rft.pages=112-115&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D14729013%26query_hl%3D5%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-pierard"><b><a href="#_ref-pierard_0" title="">^</a></b> <cite style="font-style:normal">Pierard-Franchimont C; De Doncker P, Cauwenbergh G, Pierard GE (1998). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9669136&amp;query_hl=14&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9669136&amp;query_hl=14&amp;itool=pubmed_docsum" rel="nofollow">Ketoconazole shampoo: effect of long-term use in androgenic alopecia.</a>". <i>Dermatology</i> <b>196</b> (4): 474-477.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Ketoconazole+shampoo%3A+effect+of+long-term+use+in+androgenic+alopecia.&amp;rft.title=Dermatology&amp;rft.jtitle=Dermatology&amp;rft.date=1998&amp;rft.volume=196&amp;rft.issue=4&amp;rft.au=Pierard-Franchimont+C&amp;rft.pages=474-477&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D9669136%26query_hl%3D14%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <a href="http://www.fetal-exposure.org/ANTIFUNGAL.html" class="external text" title="http://www.fetal-exposure.org/ANTIFUNGAL.html" rel="nofollow">Ketoconazole-(P)</a>. Illinois Teratogen Inforamation Service. Retrieved on <a href="../../../2/0/0/2006.html" title="2006">2006</a>-<a href="../../../a/u/g/August_9.html" title="August 9">08-09</a>.</li>
<li id="_note-habib"><b><a href="#_ref-habib_0" title="">^</a></b> <cite style="font-style:normal">Habib FK; Ross M, Ho CK, Lyons V, Chapman K (2005 Mar 20). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15543614&amp;query_hl=16&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15543614&amp;query_hl=16&amp;itool=pubmed_docsum" rel="nofollow">Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.</a>". <i>Int J Cancer</i> <b>114</b> (2): 190-194.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Serenoa+repens+%28Permixon%29+inhibits+the+5alpha-reductase+activity+of+human+prostate+cancer+cell+lines+without+interfering+with+PSA+expression.&amp;rft.title=Int+J+Cancer&amp;rft.jtitle=Int+J+Cancer&amp;rft.date=2005+Mar+20&amp;rft.volume=114&amp;rft.issue=2&amp;rft.au=Habib+FK&amp;rft.pages=190-194&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D15543614%26query_hl%3D16%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-prager">^ <a href="#_ref-prager_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-prager_1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal">Prager N; Bickett K, French N, Marcovici G (2002 Apr 8). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12006122&amp;query_hl=16&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12006122&amp;query_hl=16&amp;itool=pubmed_docsum" rel="nofollow">A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia.</a>". <i>J Altern Complement Med</i> <b>8</b> (2): 143-152.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+randomized%2C+double-blind%2C+placebo-controlled+trial+to+determine+the+effectiveness+of+botanically+derived+inhibitors+of+5-alpha-reductase+in+the+treatment+of+androgenetic+alopecia.&amp;rft.title=J+Altern+Complement+Med&amp;rft.jtitle=J+Altern+Complement+Med&amp;rft.date=2002+Apr+8&amp;rft.volume=8&amp;rft.issue=2&amp;rft.au=Prager+N&amp;rft.pages=143-152&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D12006122%26query_hl%3D16%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-marks"><b><a href="#_ref-marks_0" title="">^</a></b> <cite style="font-style:normal">Marks LS; Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE (May, 2001). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11337315&amp;query_hl=16&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11337315&amp;query_hl=16&amp;itool=pubmed_docsum" rel="nofollow">Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.</a>". <i>Urology</i> <b>57</b> (5): 999-1005.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Tissue+effects+of+saw+palmetto+and+finasteride%3A+use+of+biopsy+cores+for+in+situ+quantification+of+prostatic+androgens.&amp;rft.title=Urology&amp;rft.jtitle=Urology&amp;rft.date=May%2C+2001&amp;rft.volume=57&amp;rft.issue=5&amp;rft.au=Marks+LS&amp;rft.pages=999-1005&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D11337315%26query_hl%3D16%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> Daly W; Seegers CA, Rubin DA, Dobridge JD, Hackney AC (Jan 2005). <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15618989&amp;query_hl=16&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15618989&amp;query_hl=16&amp;itool=pubmed_docsum" rel="nofollow">Relationship between stress hormones and testosterone with prolonged endurance exercise</a> 375-380.</li>
<li id="_note-barnard1"><b><a href="#_ref-barnard1_0" title="">^</a></b> <cite style="font-style:normal">Barnard RJ; Aronson WJ, Tymchuk CN, Ngo TH (Nov. 2002). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12458975&amp;query_hl=10&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12458975&amp;query_hl=10&amp;itool=pubmed_docsum" rel="nofollow">Prostate cancer: another aspect of the insulin-resistance syndrome?</a>". <i>Obes Rev</i> <b>3</b> (4): 303-308.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Prostate+cancer%3A+another+aspect+of+the+insulin-resistance+syndrome%3F&amp;rft.title=Obes+Rev&amp;rft.jtitle=Obes+Rev&amp;rft.date=Nov.+2002&amp;rft.volume=3&amp;rft.issue=4&amp;rft.au=Barnard+RJ&amp;rft.pages=303-308&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D12458975%26query_hl%3D10%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-barnard2"><b><a href="#_ref-barnard2_0" title="">^</a></b> <cite style="font-style:normal">Barnard RJ; Aronson WJ (2005). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15648182&amp;query_hl=10&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15648182&amp;query_hl=10&amp;itool=pubmed_docsum" rel="nofollow">Preclinical models relevant to diet, exercise, and cancer risk.</a>". <i>Recent Results Cancer Res.</i> <b>166</b>: 47-61.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Preclinical+models+relevant+to+diet%2C+exercise%2C+and+cancer+risk.&amp;rft.title=Recent+Results+Cancer+Res.&amp;rft.jtitle=Recent+Results+Cancer+Res.&amp;rft.date=2005&amp;rft.volume=166&amp;rft.au=Barnard+RJ&amp;rft.pages=47-61&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D15648182%26query_hl%3D10%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-joffe"><b><a href="#_ref-joffe_0" title="">^</a></b> <cite style="font-style:normal">Joffe HV; Ridker PM, Manson JE, Cook NR, Buring JE, Rexrode KM (Feb 2006). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16216530&amp;query_hl=10&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16216530&amp;query_hl=10&amp;itool=pubmed_docsum" rel="nofollow">Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease.</a>". <i>Ann Epidemiol</i> <b>16</b> (2): 105-112.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Sex+hormone-binding+globulin+and+serum+testosterone+are+inversely+associated+with+C-reactive+protein+levels+in+postmenopausal+women+at+high+risk+for+cardiovascular+disease.&amp;rft.title=Ann+Epidemiol&amp;rft.jtitle=Ann+Epidemiol&amp;rft.date=Feb+2006&amp;rft.volume=16&amp;rft.issue=2&amp;rft.au=Joffe+HV&amp;rft.pages=105-112&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D16216530%26query_hl%3D10%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-cikim"><b><a href="#_ref-cikim_0" title="">^</a></b> <cite style="font-style:normal">Cikim AS; Ozbey N, Sencer E, Molvalilar S, Orhan Y (Oct. 2004). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16295051&amp;query_hl=1&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16295051&amp;query_hl=1&amp;itool=pubmed_docsum" rel="nofollow">Associations among sex hormone binding globulin concentrations and characteristics of the metabolic syndrome in obese women</a>". <i>Diabetes Nutr Metab.</i> <b>17</b> (5): 290-295.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Associations+among+sex+hormone+binding+globulin+concentrations+and+characteristics+of+the+metabolic+syndrome+in+obese+women&amp;rft.title=Diabetes+Nutr+Metab.&amp;rft.jtitle=Diabetes+Nutr+Metab.&amp;rft.date=Oct.+2004&amp;rft.volume=17&amp;rft.issue=5&amp;rft.au=Cikim+AS&amp;rft.pages=290-295&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D16295051%26query_hl%3D1%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-heald"><b><a href="#_ref-heald_0" title="">^</a></b> <cite style="font-style:normal">Heald AH; Anderson SG, Ivison F, Riste L, Laing I, Cruickshank JK, Gibson JM (Oct. 2005). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16235154&amp;query_hl=1&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16235154&amp;query_hl=1&amp;itool=pubmed_docsum" rel="nofollow">Low sex hormone binding globulin is a potential marker for the metabolic syndrome in different ethnic groups</a>". <i>Exp Clin Endocrinol Diabetes</i> <b>113</b> (9): 522-528.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Low+sex+hormone+binding+globulin+is+a+potential+marker+for+the+metabolic+syndrome+in+different+ethnic+groups&amp;rft.title=Exp+Clin+Endocrinol+Diabetes&amp;rft.jtitle=Exp+Clin+Endocrinol+Diabetes&amp;rft.date=Oct.+2005&amp;rft.volume=113&amp;rft.issue=9&amp;rft.au=Heald+AH&amp;rft.pages=522-528&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3Dpubmed%26dopt%3DAbstract%26list_uids%3D16235154%26query_hl%3D1%26itool%3Dpubmed_docsum">&#160;</span></li>
<li id="_note-webmd"><b><a href="#_ref-webmd_0" title="">^</a></b> <a href="http://my.webmd.com/content/article/96/103836.htm?z=3734_00000_1000_qd_01" class="external text" title="http://my.webmd.com/content/article/96/103836.htm?z=3734_00000_1000_qd_01" rel="nofollow">Hair Cloning Nears Reality as Baldness Cure</a>. Webmd.com (Nov. 4, 2004). Retrieved on <a href="../../../2/0/0/2006.html" title="2006">2006</a>-<a href="../../../a/u/g/August_10.html" title="August 10">08-10</a>.</li>
<li id="_note-cbs2chicago"><b><a href="#_ref-cbs2chicago_0" title="">^</a></b> <a href="http://cbs2chicago.com/health/health_story_075114234.html" class="external text" title="http://cbs2chicago.com/health/health_story_075114234.html" rel="nofollow">Big Baldness Breakthrough?</a>. Associated Press (Mar. 15, 2004). Retrieved on <a href="../../../2/0/0/2006.html" title="2006">2006</a>-<a href="../../../a/u/g/August_10.html" title="August 10">08-10</a>.</li>
<li id="_note-azelaic"><b><a href="#_ref-azelaic_0" title="">^</a></b> <cite style="font-style:normal">Stamatiadis D; Bulteau-Portois MC, Mowszowicz I (Nov. 1988). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=3207614&amp;itool=iconabstr&amp;query_hl=7&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=3207614&amp;itool=iconabstr&amp;query_hl=7&amp;itool=pubmed_docsum" rel="nofollow">Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid</a>". <i>Br J Dermatol</i> <b>119</b> (5): 627-632.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Inhibition+of+5+alpha-reductase+activity+in+human+skin+by+zinc+and+azelaic+acid&amp;rft.title=Br+J+Dermatol&amp;rft.jtitle=Br+J+Dermatol&amp;rft.date=Nov.+1988&amp;rft.volume=119&amp;rft.issue=5&amp;rft.au=Stamatiadis+D&amp;rft.pages=627-632&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fdb%3Dpubmed%26cmd%3DRetrieve%26dopt%3DAbstractPlus%26list_uids%3D3207614%26itool%3Diconabstr%26query_hl%3D7%26itool%3Dpubmed_docsum">&#160;</span></li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../b/a/l/Baldness_treatments.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.battleagainstbald" class="external text" title="http://www.battleagainstbald" rel="nofollow">Battle Against Bald</a> Follow the results of Seth Garon’s hair surgery.</li>
<li><a href="http://www.hairlossdocslist.com/ImportantQuestions/tabid/104/Default.aspx" class="external text" title="http://www.hairlossdocslist.com/ImportantQuestions/tabid/104/Default.aspx" rel="nofollow">Questions to ask your Physician</a> Important Questions to ask any Hair Transplant Surgeon upon initial examination</li>
<li><a href="http://www.baldingblog.com" class="external text" title="http://www.baldingblog.com" rel="nofollow">Balding blog</a> Answers the questions about hair loss and hair restoration techniques including hair transplant, medical therapy, topicals and new developments in this area.</li>
<li><a href="http://www.ushairrestoration.com" class="external text" title="http://www.ushairrestoration.com" rel="nofollow">Hair restoration</a> General information on hair loss and its treatment.</li>
<li><a href="http://www.aafp.org/afp/990415ap/2189.html" class="external text" title="http://www.aafp.org/afp/990415ap/2189.html" rel="nofollow">"Medical Treatments for Balding in Men,"</a> April 1999, <i>American Family Physician</i> (medical journal)</li>
<li><a href="http://nahrs.org/faqs/mphl.aspx" class="external text" title="http://nahrs.org/faqs/mphl.aspx" rel="nofollow">North American Hair Research Society</a> Frequently asked questions</li>
<li><a href="http://www.ahlc.org/MembersDir.htm" class="external text" title="http://www.ahlc.org/MembersDir.htm" rel="nofollow">Directory of Specialists by Region</a> from the American Hair Loss Council</li>
<li><a href="http://www.timesonline.co.uk/article/0,,8125-1584988,00.html" class="external text" title="http://www.timesonline.co.uk/article/0,,8125-1584988,00.html" rel="nofollow">Health Alternatives:</a> zinc, silica, methylsulphonylmethane (MSM) and cod-liver oil, to slow down the process.</li>
<li><a href="http://www.hair-loss.org" class="external text" title="http://www.hair-loss.org" rel="nofollow">Commercial treatment reviews</a> Examines hair loss products, and the claims made by their manufacturers.</li>
<li><a href="http://people.howstuffworks.com/hair-replacement.htm" class="external text" title="http://people.howstuffworks.com/hair-replacement.htm" rel="nofollow">How Hair Replacement Works</a> Covers oral medications, hair transplant surgery, and topical treatments.</li>
<li><a href="http://www.alopeciaonline.org.uk/" class="external text" title="http://www.alopeciaonline.org.uk/" rel="nofollow">Alopecia UK</a></li>
<li><a href="http://www.hairscientists.org/index.htm" class="external text" title="http://www.hairscientists.org/index.htm" rel="nofollow">The Trichological Society</a></li>
<li><a href="http://regrow-hair.org/" class="external text" title="http://regrow-hair.org/" rel="nofollow">How to Regrow Hair</a> Alternative ways to treat hair loss</li>
</ul>

<!-- 
Pre-expand include size: 103254 bytes
Post-expand include size: 45756 bytes
Template argument size: 30215 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../b/a/l/Baldness_treatments.html">http://en.wikipedia.org../../../b/a/l/Baldness_treatments.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../a/r/t/Category%7EArticles_with_unsourced_statements_since_February_2007_f7dc.html" title="Category:Articles with unsourced statements since February 2007">Articles with unsourced statements since February 2007</a></span> | <span dir='ltr'><a href="../../../a/l/l/Category%7EAll_articles_with_unsourced_statements_2f67.html" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></span> | <span dir='ltr'><a href="../../../d/e/r/Category%7EDermatology_8511.html" title="Category:Dermatology">Dermatology</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../b/a/l/Baldness_treatments.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../b/a/l/Talk%7EBaldness_treatments_5fbb.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Baldness_treatments">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 17:53, 22 March 2007 by Wikipedia user Pondle. Based on work by Wikipedia user(s) <a href="../../../d/a/v/User%7EDavid_Gerard_df91.html" title="User:David Gerard">David Gerard</a>, <a href="../../../c/m/d/User%7ECmdrObot_0605.html" title="User:CmdrObot">CmdrObot</a>, <a href="../../../s/a/s/User%7ESasquatch_97db.html" title="User:Sasquatch">Sasquatch</a>, Jurap267, Moonlingio, <a href="../../../a/b/u/User%7EAbu_badali_cd78.html" title="User:Abu badali">Abu badali</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, Riku p, Bavatar, <a href="../../../m/a/d/User%7EMadchester_c727.html" title="User:Madchester">Madchester</a>, <a href="../../../d/a/n/User%7EDannyBoy7783_17ac.html" title="User:DannyBoy7783">DannyBoy7783</a>, <a href="../../../m/a/d/User%7EMadmedea_0f30.html" title="User:Madmedea">Madmedea</a>, <a href="../../../d/a/v/User%7EDavidruben_76a6.html" title="User:Davidruben">Davidruben</a>, <a href="../../../g/r/a/User%7EGravityFong_b837.html" title="User:GravityFong">GravityFong</a>, <a href="../../../m/e/n/User%7EMeno25_2b0b.html" title="User:Meno25">Meno25</a>, <a href="../../../p/a/t/User%7EPatinthehat1_2bf4.html" title="User:Patinthehat1">Patinthehat1</a>, <a href="../../../o/m/e/User%7EOmegatron_4264.html" title="User:Omegatron">Omegatron</a>, Rauglothgor, <a href="../../../a/l/i/User%7EAlison_304c.html" title="User:Alison">Alison</a>, <a href="../../../n/a/w/User%7ENawlinWiki_2ff5.html" title="User:NawlinWiki">NawlinWiki</a>, CainIV, <a href="../../../n/e/t/User%7ENetsnipe_10c5.html" title="User:Netsnipe">Netsnipe</a>, <a href="../../../g/r/a/User%7EGraemeL_c5a8.html" title="User:GraemeL">GraemeL</a>, <a href="../../../g/w/e/User%7EGwernol_c4bf.html" title="User:Gwernol">Gwernol</a>, <a href="../../../a/p/e/User%7EApers0n_d5e5.html" title="User:Apers0n">Apers0n</a>, <a href="../../../j/i/m/User%7EJim_Douglas_5faf.html" title="User:Jim Douglas">Jim Douglas</a>, Wolforama, <a href="../../../d/r/a/User%7EDrake222_5050.html" title="User:Drake222">Drake222</a>, Sjtarr, <a href="../../../d/u/n/User%7EDuncharris_e9cb.html" title="User:Duncharris">Duncharris</a>, Jackfirst, <a href="../../../p/p/r/User%7EPproctor_c510.html" title="User:Pproctor">Pproctor</a>, <a href="../../../n/e/i/User%7ENeil916_fb6c.html" title="User:Neil916">Neil916</a>, <a href="../../../d/a/n/User%7EDancter_895c.html" title="User:Dancter">Dancter</a>, <a href="../../../w/i/s/User%7EWiserd911_d9ff.html" title="User:Wiserd911">Wiserd911</a>, <a href="../../../m/r/2E/User%7EMr._Lefty_bcf9.html" title="User:Mr. Lefty">Mr. Lefty</a>, <a href="../../../d/a/v/User%7EDavidone_161a.html" title="User:Davidone">Davidone</a>, <a href="../../../c/a/c/User%7ECactus.man_4fe2.html" title="User:Cactus.man">Cactus.man</a>, <a href="../../../a/a/r/User%7EAaron_Brenneman_d498.html" title="User:Aaron Brenneman">Aaron Brenneman</a>, Shoppingcart, <a href="../../../p/a/s/User%7EPascal666_71a1.html" title="User:Pascal666">Pascal666</a>, <a href="../../../e/d/g/User%7EEdgar181_7e9b.html" title="User:Edgar181">Edgar181</a>, <a href="../../../l/o/r/User%7ELord_Voldemort_ca3f.html" title="User:Lord Voldemort">Lord Voldemort</a>, <a href="../../../r/e/b/User%7ERebelguys2_63db.html" title="User:Rebelguys2">Rebelguys2</a>, Georgios Tsalikis, <a href="../../../j/o/e/User%7EJoeBot_e8e1.html" title="User:JoeBot">JoeBot</a>, JeromePelayo, <a href="../../../j/r/g/User%7EJRGBruno_2e71.html" title="User:JRGBruno">JRGBruno</a>, StrangeAttractor, <a href="../../../w/i/s/User%7EWisco_d9f1.html" title="User:Wisco">Wisco</a>, <a href="../../../a/d/d/User%7EAddps4cat_f103.html" title="User:Addps4cat">Addps4cat</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../s/i/r/User%7ESir_Paul_8b76.html" title="User:Sir Paul">Sir Paul</a>, Hairloss expert, Allweb99, Sharp45, Waterguy, <a href="../../../p/e/a/User%7EPearle_6f07.html" title="User:Pearle">Pearle</a>, <a href="../../../r/a/l/User%7ERalphael_0eaf.html" title="User:Ralphael">Ralphael</a>, <a href="../../../n/e/c/User%7ENectarflowed_3ba7.html" title="User:Nectarflowed">Nectarflowed</a>, <a href="../../../n/u/g/User%7ENuggetboy_c60a.html" title="User:Nuggetboy">Nuggetboy</a>, <a href="../../../s/f/a/User%7ESfahey_e531.html" title="User:Sfahey">Sfahey</a>, <a href="../../../s/h/a/User%7EShakti86_fba8.html" title="User:Shakti86">Shakti86</a>, Wikster E, <a href="../../../f/i/b/User%7EFibonacci_80f7.html" title="User:Fibonacci">Fibonacci</a>, <a href="../../../s/o/p/User%7ESophitus_c635.html" title="User:Sophitus">Sophitus</a>, <a href="../../../s/i/m/User%7ESimonP_1010.html" title="User:SimonP">SimonP</a> and <a href="../../../a/l/a/User%7EAlai_39a8.html" title="User:Alai">Alai</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
